We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Hungarian drugmaker Richter Gedeon Nyrt. (RICHTER.BU) said Thursday it plans to move schizophrenia drug cariprazine into late-stage testing early next year after the experimental drug showed...
Hungarian drug maker Richter Gedeon Nyrt. (RICHTER.BU) and Forest Laboratories Inc. (FRX) announced positive drug test results on cariprazine Thursday in a stock exchange filing. "The results...
-- Once-a-day tablet Daxas(R) (roflumilast) is a first-in-class treatment under development targeting inflammation, the underlying cause of chronic obstructive pulmonary disease (COPD) ZURICH...
India's Glenmark Pharmaceuticals Ltd. (532296.BY) and U.S.-based Forest Laboratories Inc. (FRX) said Wednesday their experimental drug failed to meet desired targets during mid-stage trials in...
India's Glenmark Pharmaceuticals Ltd. (532296.BY) and U.S.-based Forest Laboratories Inc. (FRX) said Wednesday their drug to treat a breathing ailment failed to meet desired targets in a mid-stage...
U.K. pharmaceutical company AstraZeneca PLC (AZN.LN) Wednesday said it inked a deal to develop and sell an experimental anti-infection treatment from Forest Laboratories Inc. (FRX) in Europe and...
NEW YORK, Aug. 10 /PRNewswire-FirstCall/ -- -- Forest Laboratories acquires exclusive commercialisation rights to Daxas in the United States in treatment of symptomatic COPD -- Nycomed...
Forest Laboratories Inc.'s (FRX) fiscal first-quarter profit rose a better-than-expected 8.2% as sales of its Namenda treatment for Alzheimer's disease and dementia jumped, more than offsetting a...
DALLAS, June 22 /PRNewswire/ -- BeaconEquity.com announces the availability of stock alerts on today's active stocks. Stock alerts highlight recent news, trading activity and relevant market...
Forest Laboratories Inc. (FRX) reported encouraging results from two late-stage studies of its ceftaroline treatment for bacterial pneumonia and said it plans to file a new drug application for...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0 | 0 | 0.01 | 0.01 | 0.009 | 668161 | 0.01 | DE |
4 | 0.003 | 42.8571428571 | 0.007 | 0.013 | 0.007 | 741060 | 0.0093702 | DE |
12 | -0.001 | -9.09090909091 | 0.011 | 0.013 | 0.007 | 669227 | 0.00882172 | DE |
26 | -0.015 | -60 | 0.025 | 0.025 | 0.007 | 564754 | 0.0138127 | DE |
52 | -0.011 | -52.380952381 | 0.021 | 0.035 | 0.007 | 495120 | 0.01803642 | DE |
156 | -0.031 | -75.6097560976 | 0.041 | 0.059 | 0.007 | 475463 | 0.03351638 | DE |
260 | -0.006 | -37.5 | 0.016 | 0.096 | 0.007 | 2234412 | 0.04641885 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions